LCTX Stock Summary and Trading Ideas (Lineage Cell Therapeutics | AMEX:LCTX)

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.

Lineage Cell Therapeutics trades on the AMEX stock market under the symbol LCTX.

As of March 27, 2026, LCTX stock price declined to $1.49 with 881,142 million shares trading.

LCTX has a beta of 1.35, meaning it tends to be more sensitive to market movements. LCTX has a correlation of 0.09 to the broad based SPY ETF.

LCTX has a market cap of $371.14 million. This is considered a Small Cap stock.

Last quarter Lineage Cell Therapeutics reported $7 million in Revenue and $.00 earnings per share. This beat revenue expectation by $5 million and exceeded earnings estimates by $.05.

In the last 3 years, LCTX traded as high as $2.09 and as low as $.37.

The top ETF exchange traded funds that LCTX belongs to (by Net Assets): VTI, VXF, IBB.

LCTX has outperformed the market in the last year with a return of +197.9%, while the SPY ETF gained +12.9%. However, in the most recent history, LCTX shares have underperformed the stock market with its stock returning -9.7% in the last 3 month period and -5.7% for the last 2 week period, while SPY has returned -7.8% and -4.5%, respectively.

LCTX support price is $1.47 and resistance is $1.59 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LCTX shares will trade within this expected range on the day.